Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF)

Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to provide both anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The clinical potency of hMSCs is based upon an initial direct hMSC effect on the pro-inflammatory and anti-microbial pathophysiology as well as...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonfield, Tracey L., Sutton, Morgan T., Fletcher, David R., Reese-Koc, Jane, Roesch, Erica A., Lazarus, Hillard M., Chmiel, James F., Caplan, Arnold I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960767/
https://www.ncbi.nlm.nih.gov/pubmed/37259368
http://dx.doi.org/10.3390/ph16020220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960767/
https://www.ncbi.nlm.nih.gov/pubmed/37259368
http://dx.doi.org/10.3390/ph16020220

Ejemplares similares